Key Holders Dump Solana Futures — What Whale Moves Signal for SOL Price
Whales and major holders are retreating from Solana futures, hinting at caution and possible further downside for SOL. With selling pressure building and key indicators turning bearish, the token’s short-term outlook remains fragile.
Solana’s price decline from highs near $230 to roughly $195 between October 7 and 14 has dampened confidence among some of its major holders.
On-chain data shows that over the past week, SOL has seen a significant drop in the number of perpetual futures positions held by its key investors, raising the risk of further downward pressure on the coin in the near term.
SOL Sentiment Turns Cautious as Large Holders Step Back
According to Nansen, whales trading Solana perpetual futures have reduced their net positions by 103% over the past week. This signals that some of the market’s largest players are closing out positions rather than doubling down.
For token TA and market updates: Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter
Solana Whale Activity. Source:
Nansen
Per the data provider, these are large investors holding coins worth more than $1 million. Reducing their net positions like this signals weakening confidence and can pressure the market, as their activity often influences smaller holders.
Moreover, the top 100 Solana addresses have reduced their perpetual futures exposure, with positions falling 70.07% over the past week.
This decline highlights a shift in sentiment among major players, who appear to be scaling back risk following the coin’s volatile price swings and last weekend’s broader market liquidation event.
These trends suggest that SOL large holders and high-value traders are exercising caution amid fading bullish momentum in the cryptocurrency market.
SOL Sellers Gain Momentum on Daily Chart
On the daily chart, SOL’s negative Balance of Power supports this bearish outlook. As of this writing, the momentum indicator is in a downtrend at -0.65.
The BoP indicator measures the strength of buyers versus sellers in the market, helping to identify momentum shifts. When its value is positive, buyers dominate the market over sellers and drive newer price gains.
Conversely, negative BoP readings signal that sellers dominate the market and are pushing prices downward.
If SOL sellers gain more strength, they could trigger a dip below the $195 price level toward $171.88.
SOL Price Analysis. Source:
TradingView
Conversely, renewed buyer interest could stabilize the SOL market and trigger a rebound to $219.21.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion
The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.
Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight
Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market
Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.
Crypto prices
More
